Investigation: Oral Tirzepatide “Drops” Sold by Willow Health
Chimicles Schwartz Kriner & Donaldson-Smith LLP is investigating the marketing and sale of so-called “oral tirzepatide drops” sold through Willow Health (also known as Willow) and potentially dispensed by Epiq Pharmacy (also known as Epiq Scripts).
What Is the Concern?
Tirzepatide is the active ingredient in Mounjaro® and Zepbound®, which are FDA-approved injectable medications. Tirzepatide is a peptide, and there is no clinical evidence establishing that it can produce a therapeutic effect when delivered orally or sublingually.
Who May Be Affected?
You may have relevant information if you:
- Purchased oral “tirzepatide drops” from Willow Health (Willow)
- Received a compounded tirzepatide product in liquid, sublingual, or drops form
- Had your prescription filled by Epiq Pharmacy (Epiq Scripts)
- Were told that the drops were equivalent to Mounjaro®, Zepbound®, or another GLP-1 medication (such as the Wegovy Pill®)
- Did not experience meaningful weight loss
- Paid significant out-of-pocket costs for the product
If You Purchased Tirzepatide Drops or Another Oral Tirzepatide Product, We Want to Hear from You
If you purchased oral tirzepatide drops from Willow Health or received tirzepatide in oral form dispensed by Epiq Pharmacy/Epiq Scripts, we would like to speak with you about your experience.
(*) Indicates required field: When communicating with us through this site or otherwise in connection with a matter for which we do not already represent you, your communication may not be treated as privileged or confidential, and does not create an attorney-client relationship between you and our Firm.
